Healthcare provider profile · identity verified

Todd R Holbrook, MD

Family Practice · EMMAUS, PA · NPI 1245231844

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	359	99
Amlodipine Besylate	Amlodipine Besylate	281	68
Levothyroxine Sodium	Levothyroxine Sodium	279	77
Omeprazole	Omeprazole	202	52
Lisinopril	Lisinopril	199	53
Metoprolol Succinate	Metoprolol Succinate	184	50
Simvastatin	Simvastatin	183	49
Rosuvastatin Calcium	Rosuvastatin Calcium	182	45
Tamsulosin Hcl	Tamsulosin Hcl	150	43
Famotidine	Famotidine	149	41
Hydrochlorothiazide	Hydrochlorothiazide	143	41
Albuterol Sulfate Hfa	Albuterol Sulfate	133	55
Escitalopram Oxalate	Escitalopram Oxalate	133	36
Pantoprazole Sodium	Pantoprazole Sodium	130	34
Losartan Potassium	Losartan Potassium	129	38
Benazepril Hcl	Benazepril Hcl	119	36
Metformin Hcl Er	Metformin Hcl	117	36
Pravastatin Sodium	Pravastatin Sodium	117	29
Jardiance	Empagliflozin	108	22
Celecoxib	Celecoxib	107	33
Montelukast Sodium	Montelukast Sodium	97	27
Fluticasone Propionate	Fluticasone Propionate	84	35
Trazodone Hcl	Trazodone Hcl	80	22
Eliquis	Apixaban	72	19
Furosemide	Furosemide	71	25
Gabapentin	Gabapentin	70	22
Metformin Hcl	Metformin Hcl	69	16
Azithromycin	Azithromycin	60	54
Alprazolam	Alprazolam	58	19
Sertraline Hcl	Sertraline Hcl	58	16
Citalopram Hbr	Citalopram Hydrobromide	57	11
Metoprolol Tartrate	Metoprolol Tartrate	56	17
Glimepiride	Glimepiride	55	17
Clopidogrel	Clopidogrel Bisulfate	54	14
Potassium Chloride	Potassium Chloride	53	13
Meloxicam	Meloxicam	49	15
Tramadol Hcl	Tramadol Hcl	48	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	48	suppressed
Atenolol	Atenolol	47	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	46	19
Duloxetine Hcl	Duloxetine Hcl	43	12
Amoxicillin	Amoxicillin	41	33
Lorazepam	Lorazepam	41	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	suppressed
Spironolactone	Spironolactone	37	suppressed
Januvia	Sitagliptin Phosphate	36	suppressed
Xarelto	Rivaroxaban	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	32	suppressed
Carvedilol	Carvedilol	32	suppressed
Desloratadine	Desloratadine	32	suppressed
Finasteride	Finasteride	32	11
Mometasone Furoate	Mometasone Furoate	32	16
Ezetimibe	Ezetimibe	29	suppressed
Tresiba Flextouch U-100	Insulin Degludec	29	suppressed
Allopurinol	Allopurinol	27	suppressed
Methylprednisolone	Methylprednisolone	27	23
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	23
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	25	suppressed
Prednisone	Prednisone	25	21
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Cefuroxime	Cefuroxime Axetil	21	20
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	20	suppressed
Colesevelam Hcl	Colesevelam Hcl	20	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	14
Meclizine Hcl	Meclizine Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	13
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Oxycontin	Oxycodone Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Torsemide	Torsemide	13	suppressed
Tri-Legest Fe	Norethindrone-E.Estradiol-Iron	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Metolazone	Metolazone	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Ozempic	Semaglutide	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error